Scroll for more

news

Nov 9, 2017 announcements

Annual award announced for medical research charities wishing to benefit from artificial intelligence

BenevolentAI, one of the world’s largest private AI companies, in partnership with the Association of Medical Research Charities (“AMRC”) announced today it has created a new award, the BenevolentAI Award, to help charities accelerate their medical research and potentially develop new treatments and therapies using artificial intelligence.

Oct 3, 2017 articles

How Close Are We to Curing ALS? A Review of Biotech’s Efforts

Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)

Aug 31, 2017 articles

This AI unicorn is disrupting the pharma industry in a big way

WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.

Aug 22, 2017 articles

BenevolentAI poaches drug discovery executive from GlaxoSmithKline

FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.

Aug 22, 2017 announcements

BenevolentAI hires Head of GSK Discovery Performance Unit as VP Drug discovery

BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.

Jul 7, 2017 articles

Machine Learning and the march towards precision medicine

Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.

Jul 5, 2017 articles

Could AI help treat Motor Neurone Disease?

We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.

Jun 15, 2017 articles

BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms

Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.

May 25, 2017 announcements

AI enabled research shows delay in onset of motor neurone disease

Sheffield and London, UK - 25 May 2017.  The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.

Apr 26, 2017 articles

9 Computational Drug Discovery Startups Using AI

Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.

Apr 25, 2017 articles

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Apr 13, 2017 articles

BenevolentAI to power small molecule drug discovery BenevolentAI to power small molecule drug discovery

This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.

Apr 11, 2017 announcements

BenevolentAI agrees partnership with medical research charity MRC technology

London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.

Mar 20, 2017 articles

BenevolentAI Q&A: Techworld meets Dr Jackie Hunter, CEO of BenevolentBio

An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI

Jan 6, 2017 articles

BenevolentAI gets The Economist thinking on biology and AI

We met with The Economist to discuss how artificial intelligence (AI) and machine learning is helping to crack and transform the scientific method.